BRAF and melanoma: Besides, research has showed that a combination of anti-PD-1/PD-L1 antibody and CTLA-4 inhibitor can improve treatment effects of patients with advanced melanoma, which was approved by the FDA in treating BRAF V600 E wild-type patients with unresectable or metastatic melanoma [41, 42].